Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582017 | 0.97 | — | — | |
| SCHEMBL4396772 | 0.75 | — | — | |
| SCHEMBL4202497 | 0.75 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL1602300 | 0.74 | TRPA1 (0.32) | — | |
| SCHEMBL6147013 | 0.74 | HSD17B10 (0.33) | — | |
| SCHEMBL1602298 | 0.74 | TRPA1 (0.32) | — | |
| SCHEMBL6147015 | 0.74 | HSD17B10 (0.33) | — | |
| SCHEMBL45553 | 0.72 | LTA4H (0.39) | — | |
| SCHEMBL3281206 | 0.70 | TRPA1 (0.33) | — | |
| SCHEMBL2373374 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105717756-B | Semi-aqueous photoresist or semiconductor manufacturing residue stripping and cleaning compositions with improved silicon passivation | 弗萨姆材料美国有限责任公司 | 2021-02-02 | — | — | CN | claimed |
| CN-109415538-B | Use of additive composition for preparing polycondensation polymer | 科莱恩塑料和涂料有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-105717756-B | Semi-aqueous photoresist or semiconductor manufacturing residue stripping and cleaning compositions with improved silicon passivation | 弗萨姆材料美国有限责任公司 | 2021-02-02 | — | — | CN | disclosed |
| US-8377935-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8138198-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE (FR) | 2012-03-20 | — | — | US | disclosed |
| EP-1453805-B1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE | 2009-09-03 | — | — | US | disclosed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | disclosed |
| US-4835157-A | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
| US-4675403-A | SIDE EFFECT REDUCTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC3 | CA1 3871/4885CA2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.